EmbarkNeuro

EmbarkNeuro is a neuroscience-focused biotech startup, founded in 2019 and headquartered in the United States. It is a portfolio company of Aditum Bio, a biotech investment firm co-founded by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman. The company's slogan, "Exploring pathways for the personalized treatment of mental health," reflects its focus on mental health treatment. EmbarkNeuro is currently evaluating a Phase II asset in patients with major depressive disorder. The company's formation followed the in-licensing of a selective vasopressin 1b receptor (V1b) antagonist (ANC-501) from Taisho Pharmaceutical Co., Ltd. The company's approach is patient-centric, collaborative, curious, and courageous. As of now, there is no information available about the last investment or the investors involved. EmbarkNeuro operates in the biotechnology, health and wellness, and life sciences industries. Overall, EmbarkNeuro's strategic focus on personalized mental health treatments and its relation to industry-leading figures such as Joe Jimenez and Dr. Mark Fishman positions the company as an innovative player in the biotech landscape.